Premium
Sublingual apomorphine solution in Parkinson's disease
Author(s) -
Panegyres Peter K,
Graham Shanthi J,
Williams Bernard K,
Higgins Barbara M,
Morris John G L
Publication year - 1991
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1991.tb101311.x
Subject(s) - apomorphine , levodopa , parkinson's disease , medicine , anesthesia , subcutaneous injection , placebo , domperidone , nausea , dopaminergic , dopamine , disease , alternative medicine , pathology
Objective: To compare the effects of single doses of oral levodopa, subcutaneous apomorphine and sublingual apomorphine. Design: Single‐blind placebo‐controlled comparative study. Setting: Subjects were admitted as day patients to the neurology ward. Patients: Five patients with idiopathic Parkinson's disease and “end of dose deterioration” entered and completed the study. Interventions: Patients were given domperidone (20 mg by mouth three times a day) to prevent nausea and apomorphine (1–3 mg by subcutaneous injection), apomorphine in glycerol (10–30 mg sublingually) or their usual levodopa regimen. Main outcome measures: Efficacy, time to onset of effect and duration of effect of oral levodopa, subcutaneous apomorphine and sublingual apomorphine. Tremor amplitude and timed pegboard and gait tasks were used as objective indices of clinical state. Results: Maximal efficacy of the three treatments was comparable ( P = 0.28–0.99). Mean latency to onset of effect of both formulations of apomorphine was less than that of levodopa ( P = 0.022–0.048) but so was the duration of effect ( P = 0.044–0.049). Conclusions: Sublingual apomorphine may be a convenient means of rapidly terminating “off” periods associated with long term levodopa therapy.